We have treated hundreds of patients with PAH with long-term intravenous prostacyclin, treprostinil, sildenafil, tadalafil, bosentan, ambrisentan, iloprost, riociguat, macitentan, and more. We accept referrals from all sources and welcome any interest or questions from health-care workers and from the general public.
· A Phase 3 trial of bardoxolone for patients with PAH is just starting.
· A trial of a new oral prostacyclin receptor agonist (oral selexipag) for patients with PAH has been completed.
· A trial of a new drug (oral ASK-1 inhibitor) for patients with PAH is no longer enrolling, patients remain on the study drug.
· Exercise training (rehabilitation) trial: Tune in soon for more info....and more!
Summary of Research Trials at Harbor-UCLA
Conventional PULMONARY ARTERIAL HYPERTENSION TREATMENT
All patients are given an in-depth medical evaluation and counseled on the risks and benefits of prostacyclin in PAH.
Initiation of prostacyclin takes approximately two days as an inpatient, and patients are usually ready to return to progressive activities upon discharge. While patients are hospitalized, their families and/or supporting members will be instructed on the use of prostacyclin, how to administer the drug, and what to do in case of an emergency.
For more information on any of the above trials, call our research coordinator, Joy at 310-222-3560